Reporting owner · CIK 0001595117
George Simeon
Visual SEC Form 4 history across 1 companies, 15 transactions and 1 filings.
DIRADARx Pharmaceuticals, Inc.
Open-market mix
100%buys
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #231482 | ADRX | George Simeon | DIR | unknown | 198k | $0 | C | 09/30 | 09/28 |
| #231481 | ADRX | George Simeon | DIR | unknown | 1.95M | $0 | C | 09/30 | 09/28 |
| #231480 | ADRX | George Simeon | DIR | unknown | 1.80M | $0 | C | 09/30 | 09/28 |
| #231479 | ADRX | George Simeon | DIR | unknown | 600k | $0 | C | 09/30 | 09/28 |
| #231478 | ADRX | George Simeon | DIR | unknown | 1.30M | $0 | C | 09/30 | 09/28 |
| #231477 | ADRX | George Simeon | DIR | unknown | 3.90M | $0 | C | 09/30 | 09/28 |
| #231476 | ADRX | George Simeon | DIR | buy | 592k | $1.00B | P | 09/30 | 09/28 |
| #231475 | ADRX | George Simeon | DIR | unknown | 169k | — | C | 09/30 | 09/28 |
| #231474 | ADRX | George Simeon | DIR | unknown | 1.66M | — | C | 09/30 | 09/28 |
| #231473 | ADRX | George Simeon | DIR | buy | 414k | $705M | P | 09/30 | 09/28 |
Latest Form 4 facts
Quick context from source filings
Latest transaction
buy at ADARx Pharmaceuticals, Inc. on Sep 28, 2026 valued at $10,074,081.
Review SEC filingLatest buy
buy at ADARx Pharmaceuticals, Inc. on Sep 28, 2026 valued at $10,074,081.
Review SEC filingLatest sale
No open-market insider sale is available.
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
4 observations · Sep 28, 2026 – Sep 28, 2026. Window ends at the latest available report, not today.
Selected observation · Sep 28, 20265,554,094 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Sep 28, 2026 | 3,334,938 | Sep 30, 2026 | View transaction |
| Sep 28, 2026 | 4,448,604 | Sep 30, 2026 | View transaction |
| Sep 28, 2026 | 4,961,501 | Sep 30, 2026 | View transaction |
| Sep 28, 2026 | 5,554,094 | Sep 30, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Sep 26
$27.2M
Transaction texture
Ownership and ticket size
Average P/S size$9.1M
Median P/S size$10.1M
Direct0
Indirect15
Sep 28, 2026unknown
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Visual map of known reporting history
George Simeon Insider Activity FAQ
SEC Form 4 context
Who is George Simeon?
George Simeon is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001595117.
Which companies has George Simeon reported transactions for?
ADARx Pharmaceuticals, Inc.
When was George Simeon's latest insider buy?
buy at ADARx Pharmaceuticals, Inc. on Sep 28, 2026 valued at $10,074,081.
When was George Simeon's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.